Zyngenia

Zyngenia develops multispecific antibody-derived biotherapeutics designed to target several biological pathways in cancer, inflammation and autoimmune diseases. Its Zybodies platform has named preclinical research programs. Founded in 2008, with operations launched in 2009, it publishes a Washington, D.C. contact address and is listed within PharmEco's research group. Current standalone staffing, management and clinical-development activity are not publicly verified.